The research desk
Semaglutide, explained.
Clear guidance on dosing, side effects, insurance and costs, grounded in product labels and published research.
Dosing, side effects and food
Understand treatment, everyday questions and the evidence behind the advice.
Weight regain after stopping semaglutide
What happened after treatment stopped, and why a withdrawal study cannot supply a tapering plan.
Does semaglutide reduce heart attack and stroke risk?
The SELECT result with the population, outcome and treatment tradeoff kept together.
Semaglutide and kidney disease: what FLOW found
Why the FLOW kidney benefit and the label’s dehydration warning answer different questions.
Semaglutide and diabetic retinopathy: reading the warning
The label’s eye warning, with existing retinopathy separated from the overall trial result.
Semaglutide sodium and acetate: why the ingredient matters
FDA’s salt-form warning and the ingredient questions a price comparison cannot answer.
Counterfeit Ozempic: what FDA’s warning says to check
Why lot numbers alone cannot authenticate a pen, and where FDA directs patients for verification.
The escalation schedule step by step, and where your own may differ from it.
The approved labels give different instructions. All of them, quoted in full.
The three sites both labels name, how to rotate them, and the pen steps as the instructions give them.
How fast weight came off in the trials, week by week, and what the label says after week 17.
Staying on a low dose of WEGOVY
What the label calls a maintenance dose, when it says to move up, and what 1.7 mg looked like in the trial.
What “microdosing” a GLP-1 means
What the label's smallest step is, what the word departs from, and what nobody has measured.
Where in the step it usually turns up, and what is a reason to call the same day.
What WEGOVY's own label reports, at what rate, against placebo, and how many people stopped.
The rates in OZEMPIC's own table, dose by dose, and why they are lower than WEGOVY's.
Both ladders from the label's own tables, and why the top of the injection's depends on the approved use.
The four steps the label sets out, the four-week gaps, and which pen delivers which dose.
Which pen holds which dose, how many doses are in one, and why a pen belongs to one person.
What the labels list, what FDA's reporting system holds, and what nobody has measured.
Side effects, and how long they last
The five both labels report most, when they peak across the weeks, and how long a single bout usually runs.
What the nickname describes, and what the published measurements actually show.
How common it was against placebo on each label, when it clusters, and the dehydration warning behind it.
The one that runs weeks rather than days, and the placebo number that says not all of it is the drug.
What the labels count, and why two 2026 studies of the same question disagree.
What actually changes about eating, and what people adjust after a step up.
The warning both labels carry about anesthesia, and the recommendation they say the data cannot support.
The two-month interval before conceiving, and what the label measured about the pill.
Neither label mentions drinking; the trial that exists tested the drug as a treatment for drinking.
Insurance and coverage
Make sense of coverage decisions, paperwork and the options after a denial.
Does insurance cover semaglutide?
What a plan is really deciding, and the steps that get a real answer for yours.
Is WEGOVY covered by insurance?
What coverage turns on, the Medicare program that started in July, and what a denial usually cites.
Prior authorization, and the appeal
What your prescriber has to submit, and the published deadlines on both sides.
What a compounded prescription is, what FDA says about the category, and why coverage is a separate question from the brand-name one.
Four published programs, and the insurance status that opens or closes each one.
Costs and provider comparisons
Look beyond the advertised price to medication, billing and the full commitment.
FDA-approved vs compounded semaglutide: what changes?
Product approval, pharmacy oversight and clinical suitability are different questions to settle before comparing prices.
One molecule, two labels: what each is approved for, how high the dose goes, and which forms exist.
The maker's own self-pay prices by dose, what insurance changes, and what a telehealth tablet is not.
The manufacturer's published prices with the date read, and what the $25 and $199 offers really do.
The manufacturer's published pen prices with the date read, and what the $25 and $50 routes require.
What FDA's application records show, and why compounded is not the same word as generic.
The coupon price turns out to be the maker's own price, and the two pages disagree on the deadline.
$3,338 against $3,888 over a first year, and what the cheaper form asks of you every morning.
What it costs as the weeks go on
Cost a stretch of treatment using one seller's own published figures.
What a semaglutide price includes
What the monthly figure is said to cover, and who actually fills the prescription.
Why two prices are usually not comparable
The kinds of number sellers publish, and why putting two side by side usually misleads.
What “starting at” actually means
A floor is not a price. What the sellers who publish only a floor leave unsaid.
The first month is not the price
Introductory figures quoted verbatim, with what each seller says happens afterwards.
What a prepaid plan commits you to
Prepay totals beside the term each one is charged over, before you agree to it.
Whether the price you are reading even says which form of the drug it buys.
Which sellers publish a dose schedule
Who prints an actual weeks-to-dose schedule before you pay, in their own words.